Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.56 |
| ▸ | ADORA3 | P0DMS8 | 8/20 | 0.54 |
| ▸ | NPSR1 | Q6W5P4 | 5/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.54 |
| ▸ | LMNA | P02545 | 4/20 | 0.54 |
| ▸ | HTT | P42858 | 3/20 | 0.54 |
| ▸ | MAPT | P10636 | 2/20 | 0.54 |
| ▸ | ADORA1 | P30542 | 7/20 | 0.52 |
| ▸ | NPC1 | O15118 | 1/20 | 0.52 |
| ▸ | USP30 | Q70CQ3 | 2/20 | 0.52 |
| ▸ | ADORA2A | P29274 | 3/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.51 |
| ▸ | MEN1 | O00255 | 3/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2317236 | 1.00 | L3MBTL1 (0.56) | L3MBTL1ADORA3NPSR1SMN1; SMN2LMNA | |
| SCHEMBL2486771 | 0.88 | ADORA3 (0.57) | ADORA3NPSR1SMN1; SMN2LMNAHTT | |
| SCHEMBL2485106 | 0.84 | ADORA3 (0.57) | ADORA3NPSR1SMN1; SMN2LMNAHTT | |
| SCHEMBL20370279 | 0.84 | USP30 (0.70) | L3MBTL1ADORA3NPSR1SMN1; SMN2LMNA | |
| SCHEMBL27838817 | 0.83 | NPSR1 (0.55) | ADORA3NPSR1SMN1; SMN2LMNAHTT | |
| SCHEMBL13257813 | 0.82 | L3MBTL1 (0.54) | L3MBTL1NPSR1SMN1; SMN2LMNAMAPT | |
| SCHEMBL3710631 | 0.82 | L3MBTL1 (0.54) | L3MBTL1NPSR1SMN1; SMN2LMNAMAPT | |
| SCHEMBL2487161 | 0.81 | ADORA3 (0.55) | ADORA3NPSR1SMN1; SMN2LMNAHTT | |
| SCHEMBL9892864 | 0.79 | MAPT (0.54) | L3MBTL1NPSR1LMNAMAPTADORA1 | |
| SCHEMBL30557537 | 0.78 | L3MBTL1 (0.77) | L3MBTL1NPSR1SMN1; SMN2LMNAHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8703761-B2 | Organic compounds | NOVARTIS AG (CH) | 2014-04-22 | — | — | US | disclosed |
| EP-2559455-A1 | Heteroaryl derivatives as DGAT1 inhibitors | Novartis AG (CH) | 2013-02-20 | — | — | EP | disclosed |
| EP-2548618-A2 | Organic compounds | Novartis AG (CH) | 2013-01-23 | — | — | EP | disclosed |
| EP-2380631-A1 | Heteroaryl derivatives as DGAT1 inhibitors | Novartis AG (CH) | 2011-10-26 | — | — | EP | disclosed |
| US-20100022513-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2010-01-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100022513-A1 | ORGANIC COMPOUNDS | DGAT1, DGAT2, SOAT1 | L3MBTL1 1161/4885ADORA3 2247/4885NPSR1 4402/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.